Skip to main content

Table 3 Comparisons between index R for 0–6 months after the start of MTX administration and RFC1, FPGS1994, GGH452, MTHFR1298, and TYMS 3'-UTR genotypes

From: Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

Genotype

n

Index R

p-value

RFC1 80

G/G

6

0.22 (0.21–0.23)

0.112

A allele

15

0.24 (0.22–0.30)

FPGS 1994

G allele

17

0.23 (0.21–0.29)

0.517

A/A

4

0.24 (0.23–0.28)

GGH 452

C/C

11

0.23 (0.22–0.29)

0.973

T allele

10

0.23 (0.22–0.26)

MTHFR 1298

A allele

19

0.23 (0.22–0.28)

0.267

C/C

2

0.27 (0.23–0.31)

TYMS 3'-UTR

−6/–6

8

0.23 (0.22–0.23)

0.301

+6 allele

13

0.25 (0.22–0.30)

  1. median (25–75th percentile)
  2. RFC1 reduced folate carrier 1, FPGS folypolyglutamate synthetase, GGH gammaglutamyl hydrolase enzyme, MTHFR methylenetetrahydrofolate reductase, TYMS thymidylate synthase